ClinicalTrials.gg
CompletedNCT06953934Updated Oct 13, 2026

A Mass Balance Study of Oral [14C] ABBV-932 in Healthy Adult Male Participants

A Phase 1 interventional study of ABBV-932 in Healthy Volunteer, sponsored by AbbVie. Completed at 1 site in Netherlands. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

Updated Oct 13, 2026Now CompletedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The main objective of this study is to assess the safety and tolerability of ABBV-932 in healthy adult male participants.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
  • ABBV-932
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥ 18.0 to ≤ 29.9.0 kg/m\^2 after rounding to the tenths decimal. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • Male participant who is not considering fathering a child or donating sperm during the study and for 100 days after the study drug administration
  • A condition of general good health, based upon the results of a medical history, physical exam

Exclusion criteria

Exclusion Criteria:

  • Has not participated in another [14C] absorption, distribution, metabolism, excretion (ADME) study with a radiodose above 0.1 MBq in the period of 12 months prior to screening.
  • Use of any medications/products known to alter drug absorption, metabolism, or excretion processes, within 30 days or within a period defined by 5 half-lives, whichever is longer, prior to study drug administration.
  • Prior exposure to ABBV-932 or cariprazine within the past 90 days.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    ABBV-932

    Participants will receive a single oral dose of ABBV-932 on day 1.

    Drug: ABBV-932

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Plasma Concentration (Cmax) of ABBV-932

    Cmax of ABBV-932

    Time frame: Up to approximately 86 days

  2. Time to Cmax (Tmax) of ABBV-932

    Tmax of ABBV-932

    Time frame: Up to approximately 86 days

  3. Terminal phase elimination rate constant (λz) of ABBV-932

    Terminal phase elimination rate constant (λz) of ABBV-932

    Time frame: Up to approximately 86 days

  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-932

    Terminal phase elimination half-life of ABBV-932

    Time frame: Up to approximately 86 days

  5. Area Under the Concentration-Time Curve From Time 0 to Time t (AUCt) of ABBV-932

    AUCt of ABBV-932

    Time frame: Up to approximately 86 days

  6. Area Under the Concentration-Time Curve From Time 0 to Infinity (AUCinf) of ABBV-932

    AUCinf of ABBV-932

    Time frame: Up to approximately 86 days

  7. Number of Participants Experiencing Adverse Events

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately 103 days

07

Study locations

1 site
  • ICON Clinical Research /ID# 270490
    Groningen, 9728 NZ, Netherlands
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2026 to primary completion in Sep 2026, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2025
First posted
May 1, 2025
StartActual
May 4, 2026
Primary completionActual
Sep 14, 2026
CompletionActual
Sep 14, 2026
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Active, not recruiting→Completed
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06953934
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
May 1, 2025
Start date
May 4, 2026
Primary completion
Sep 14, 2026
Completion
Sep 14, 2026
Last update
Oct 13, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABBV-932

Start the discussion